EyePoint, Inc. · NASDAQ
Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
At least 5 tagged posts are needed.
How do you feel about EYPT?
Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio NowEyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.
GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.
Headlines link to the publisher. Not investment advice.
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $EYPT
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
